Nyxoah S.A. (NYXH)
9.68
0.30 (3.25%)
At close: Jan 15, 2025, 4:10 PM
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.
| Country | BE |
| IPO Date | Apr 28, 2021 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, BE | |
| Website | https://www.nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857190 |
| CUSIP Number | n/a |
| ISIN Number | BE0974358906 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer & Executive Director |
| Bruno Onkelinx | Chief Technology Officer |
| John Landry | Chief Financial Officer |
| An Moonen | General Counsel |
| Jeyakumar Subbaroyan | Chief Clinical Officer |
| Loic Moreau | President of International |
| Maggie McGowan | Chief HR Officer |
| Mikaela Kirkwood | Corporate Communication & Investor Relations Manager |
| Remi Renard | Chief of Staff |
| Robert Taub MBA | Co-Founder & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 02, 2025 | 6-K | Filing |
| Dec 13, 2024 | 6-K | Filing |
| Dec 02, 2024 | 6-K | Filing |
| Nov 20, 2024 | 6-K | Filing |
| Nov 18, 2024 | 6-K | Filing |
| Nov 08, 2024 | S-8 | Filing |
| Nov 06, 2024 | 6-K | Filing |
| Nov 05, 2024 | 6-K | Filing |
| Oct 28, 2024 | 6-K | Filing |
| Oct 15, 2024 | 6-K | Filing |